Skip to content

Maravai LifeSciences

US · MRVI #3116 by market cap Listed 2020
6.98 -0.21 -2.92%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 18 in the most recent period (2026/Q3).
  • Total institutional ownership rose 3.6 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
103.13% +3.64pp
Institutions
229 +18
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund51.02%
Hedge Fund29.96%
VC/PE Fund13.50%
Public Company3.56%
Individual/Insider3.55%
Private Company2.51%
Insurance Company1.54%
Sovereign Wealth Fund0.39%
Family Office/Trust0.43%
Government Pension Fund0.39%

Top holders as of 2026-06-30

GTCR LLC 13.50% · 20.15M sh
BlackRock 7.08% · 10.56M sh
Braidwell LP 5.83% · 8.70M sh
Millennium Management LLC 5.21% · 7.77M sh
12 West Capital Management LP 4.73% · 7.06M sh
FMR 4.62% · 6.89M sh
Vanguard Capital Management, LLC 3.52% · 5.25M sh
Ophir Asset Management Pty Ltd 3.23% · 4.83M sh
Renaissance Technologies Corp. 2.67% · 3.99M sh
Deutsche Asset & Wealth Management 2.89% · 4.30M sh
First Eagle Investment Management, LLC 2.20% · 3.28M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 27 buys · 23 sells

NameRoleStake
GTCR LLC -- 13.50%
Bernd Brust Chief Executive Officer 0.59%
Peter Leddy Former Executive Vice President 0.46%
Kevin Herde Former Chief Financial Officer 0.41%
William Martin Former Chief Executive Officer 0.25%
Gregory Lucier Independent Director 0.18%
Christine Dolan Executive VP & GM of Cygnus Technologies 0.17%
Robert Eckert Chairperson 0.17%
Rebecca Buzzeo Former Executive Vice President 0.15%
Susannah Gray Independent Director 0.11%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-08 Bernd Brust Chief Executive Officer Sale to Issuer -29,250 $7.52
2026-10-29 Rajesh Asorpota EVP & Chief Financial Officer Sale to Issuer -5,466 $8.46
2026-10-07 Bernd Brust Chief Executive Officer Sale to Issuer -29,250 $7.43
2026-09-29 Rajesh Asorpota EVP & Chief Financial Officer Sale to Issuer -5,465 $7.65
2026-09-07 Bernd Brust Chief Executive Officer Sale to Issuer -29,250 $7.32
2026-08-30 Rajesh Asorpota EVP & Chief Financial Officer Sale to Issuer -5,465 $7.68
2026-08-09 Bernd Brust Chief Executive Officer Sale to Issuer -29,250 $6.23
2026-07-29 Rajesh Asorpota EVP & Chief Financial Officer Sale to Issuer -5,465 $6.59
2026-07-07 Bernd Brust Chief Executive Officer Sale to Issuer -29,250 $5.92
2026-06-29 Rajesh Asorpota EVP & Chief Financial Officer Sale to Issuer -65,584 $6.39
2026-06-09 Kurt Oreshack General Counsel Automatic Disposition -50,000 $5.06–5.10
2026-06-09 Kurt Oreshack General Counsel Intent to Sell (Form 144) -25,000 $5.10
2026-06-08 Gregory Lucier Independent Director Other Acquisition +46,293 --
2026-06-08 Gregory Lucier Independent Director Other Disposition -46,293 --
2026-06-08 Kurt Oreshack General Counsel Intent to Sell (Form 144) -25,000 $5.06
2026-06-07 Bernd Brust Chief Executive Officer Sale to Issuer -351,001 $5.02
2026-05-25 John DeFord Independent Director Other Acquisition +46,293 --
2026-05-25 Constantine Mihas Non-Independent Director Other Acquisition +46,293 --
2026-05-25 Sean Cunningham Non-Independent Director Other Acquisition +46,293 --
2026-05-25 Gregory Lucier Independent Director Other Acquisition +46,293 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Maravai LifeSciences discussion 0 comments

Add a comment